Maintenance of protein homeostasis and organelle integrity and function is critical for
cellular homeostasis and cell viability. Autophagy is the principal mechanism that mediates …

Covalent drugs have been used to treat diseases for more than a century, but tools that
facilitate the rational design of covalent drugs have emerged more recently. The purposeful …

Abstract Background Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was
designed to have high potency and selectivity. Methods In a phase 1 study, we evaluated …

Targeted protein degradation (TPD) is an emerging therapeutic modality with the potential to
tackle disease-causing proteins that have historically been highly challenging to target with …

Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Mutations in the KRAS oncogene are found in more than 90% of patients with pancreatic
ductal adenocarcinoma (PDAC), with Gly-to-Asp mutations (KRAS G12D) being the most …

Since the initial clinical approval in the late 1990s and remarkable anticancer effects for
certain types of cancer, molecular targeted therapy utilizing small molecule agents or …

Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has greatly improved
the clinical efficacy of malignant tumor therapy. ICI-mediated antitumor responses depend …

Abstract On May 28, 2021, the FDA granted accelerated approval to sotorasib (Lumakras,
Amgen) for the treatment of adults with advanced non–small cell lung cancer (NSCLC) with …

As a type of lytic cell death driven by unrestricted lipid peroxidation and subsequent plasma
membrane damage, ferroptosis occurs and develops because of sophisticated signals and …